1-160838686-C-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_016382.4(CD244):c.767-168G>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.525 in 630,148 control chromosomes in the GnomAD database, including 89,424 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.48 ( 18609 hom., cov: 31)
Exomes 𝑓: 0.54 ( 70815 hom. )
Consequence
CD244
NM_016382.4 intron
NM_016382.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.0540
Publications
5 publications found
Genes affected
CD244 (HGNC:18171): (CD244 molecule) This gene encodes a cell surface receptor expressed on natural killer (NK) cells (and some T cells) that mediate non-major histocompatibility complex (MHC) restricted killing. The interaction between NK-cell and target cells via this receptor is thought to modulate NK-cell cytolytic activity. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.558 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.478 AC: 72632AN: 151856Hom.: 18601 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
72632
AN:
151856
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.539 AC: 257956AN: 478174Hom.: 70815 Cov.: 5 AF XY: 0.540 AC XY: 137508AN XY: 254440 show subpopulations
GnomAD4 exome
AF:
AC:
257956
AN:
478174
Hom.:
Cov.:
5
AF XY:
AC XY:
137508
AN XY:
254440
show subpopulations
African (AFR)
AF:
AC:
3758
AN:
13032
American (AMR)
AF:
AC:
12563
AN:
20760
Ashkenazi Jewish (ASJ)
AF:
AC:
8714
AN:
14418
East Asian (EAS)
AF:
AC:
12626
AN:
31678
South Asian (SAS)
AF:
AC:
24512
AN:
47530
European-Finnish (FIN)
AF:
AC:
19237
AN:
34588
Middle Eastern (MID)
AF:
AC:
1253
AN:
2124
European-Non Finnish (NFE)
AF:
AC:
160969
AN:
286940
Other (OTH)
AF:
AC:
14324
AN:
27104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
5935
11869
17804
23738
29673
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.478 AC: 72669AN: 151974Hom.: 18609 Cov.: 31 AF XY: 0.477 AC XY: 35420AN XY: 74268 show subpopulations
GnomAD4 genome
AF:
AC:
72669
AN:
151974
Hom.:
Cov.:
31
AF XY:
AC XY:
35420
AN XY:
74268
show subpopulations
African (AFR)
AF:
AC:
11634
AN:
41414
American (AMR)
AF:
AC:
8526
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
AC:
2141
AN:
3468
East Asian (EAS)
AF:
AC:
2138
AN:
5150
South Asian (SAS)
AF:
AC:
2434
AN:
4818
European-Finnish (FIN)
AF:
AC:
5768
AN:
10544
Middle Eastern (MID)
AF:
AC:
176
AN:
294
European-Non Finnish (NFE)
AF:
AC:
38232
AN:
67970
Other (OTH)
AF:
AC:
1083
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1808
3615
5423
7230
9038
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.